{"DataElement":{"publicId":"2388702","version":"1","preferredName":"Protocol Temozolomide Agent Administered Course Type","preferredDefinition":"the cycle of temozolomide, a cytotoxic alkylating agent that is a triazene analog of dacarbazine with antineoplastic activity, being administered as defined by the protocol.","longName":"PR_TEM_AGT_ADM_CR_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2388699","version":"1","preferredName":"Protocol Temozolomide Agent Administered","preferredDefinition":"information related to the protocol-defined administration of temozolomide, a cytotoxic alkylating agent that is a triazene analog of dacarbazine with antineoplastic activity.","longName":"PROT_TEMOZ_AGT_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2388697","version":"1","preferredName":"Protocol Temozolomide Agent","preferredDefinition":"An action plan for a clinical trial.  The plan states what the study will do, how, and why.  It explains how many people will be in it, who is eligible to participate, what study agents or other interventions they will be given, what tests they will receive and how often, and what information will be gathered.:A triazene analog of dacarbazine with antineoplastic activity.  As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of  DNA replication.  Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. (NCI04):An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","longName":"C25320:C1244:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Study Protocol","conceptCode":"C25320","definition":"A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the study, but these could be represented in other protocol referenced documents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Temozolomide","conceptCode":"C1244","definition":"A triazene analog of dacarbazine with antineoplastic activity.  As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of DNA replication. Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE0FD98C-B46F-595D-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-11","modifiedBy":"ONEDATA","dateModified":"2005-08-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE0FD98C-B470-595D-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-11","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2388701","version":"1","preferredName":"Temozolomide Course Type","preferredDefinition":"the cycle of temozolomide, a cytotoxic alkylating agent that is a triazene analog of dacarbazine with antineoplastic activity, being administered as defined by the protocol.","longName":"TEMOZ_CRSE_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"TMZ days 1-5 of 28 day cycle 12 cycle maximum","valueDescription":"TMZ days 1-5 of 28 day cycle 12 cycle maximum","ValueMeaning":{"publicId":"2575927","version":"1","preferredName":"TMZ days 1-5 of 28 day cycle 12 cycle maximum","longName":"2575927","preferredDefinition":"TMZ days 1-5 of 28 day cycle 12 cycle maximum","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5A4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-11","modifiedBy":"CAMPBELB","dateModified":"2005-08-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FE1331D0-F147-3001-E034-0003BA3F9857","beginDate":"2005-08-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-11","modifiedBy":"ONEDATA","dateModified":"2005-08-11","deletedIndicator":"No"},{"value":"Concurrent RT and TMZ (42 days)","valueDescription":"Concurrent RT and TMZ (42 days)","ValueMeaning":{"publicId":"2575928","version":"1","preferredName":"Concurrent RT and TMZ (42 days)","longName":"2575928","preferredDefinition":"Concurrent RT and TMZ (42 days)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5A5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-11","modifiedBy":"CAMPBELB","dateModified":"2005-08-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FE1331D0-F143-3001-E034-0003BA3F9857","beginDate":"2005-08-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-11","modifiedBy":"ONEDATA","dateModified":"2005-08-11","deletedIndicator":"No"},{"value":"TMZ days 1-21 of 28 day cycle 12 cycle maximum","valueDescription":"TMZ days 1-21 of 28 day cycle 12 cycle maximum","ValueMeaning":{"publicId":"2575926","version":"1","preferredName":"TMZ days 1-21 of 28 day cycle 12 cycle maximum","longName":"2575926","preferredDefinition":"TMZ days 1-21 of 28 day cycle 12 cycle maximum","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5A3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-11","modifiedBy":"CAMPBELB","dateModified":"2005-08-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FE1331D0-F14B-3001-E034-0003BA3F9857","beginDate":"2005-08-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-11","modifiedBy":"ONEDATA","dateModified":"2005-08-11","deletedIndicator":"No"},{"value":"Concurrent RT and TMZ","valueDescription":"Concurrent RT and TMZ","ValueMeaning":{"publicId":"2800760","version":"1","preferredName":"Concurrent RT and TMZ","longName":"2800760","preferredDefinition":"Concurrent RT and TMZ","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BA8C9D9-215F-6A9F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-14","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5BA8D106-929A-6D06-E044-0003BA3F9857","beginDate":"2008-11-14","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-14","modifiedBy":"ONEDATA","dateModified":"2008-11-14","deletedIndicator":"No"},{"value":"Concurrent RT, TMZ, and BEV / placebo","valueDescription":"Concurrent RT, TMZ, and BEV / placebo","ValueMeaning":{"publicId":"2800761","version":"1","preferredName":"Concurrent RT, TMZ, and BEV / placebo","longName":"2800761","preferredDefinition":"Concurrent RT, TMZ, and BEV / placebo","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BA8CCBC-6B47-6E65-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-14","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5BA8D106-92AC-6D06-E044-0003BA3F9857","beginDate":"2008-11-14","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-14","modifiedBy":"ONEDATA","dateModified":"2008-11-14","deletedIndicator":"No"},{"value":"Adjuvant TMZ and BEV / placebo","valueDescription":"Adjuvant TMZ and BEV / placebo","ValueMeaning":{"publicId":"2800762","version":"1","preferredName":"Adjuvant TMZ and BEV / placebo","longName":"2800762","preferredDefinition":"Adjuvant TMZ and BEV / placebo","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BA8CF16-182E-6F19-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-14","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5BA8D106-92BE-6D06-E044-0003BA3F9857","beginDate":"2008-11-14","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-14","modifiedBy":"ONEDATA","dateModified":"2008-11-14","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2388700","version":"1","preferredName":"Course Type","preferredDefinition":"A period of protocol-prescribed activity or intervention.:Type; a subdivision of a particular kind of thing.","longName":"C25379:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Course","conceptCode":"C25379","definition":"Passage through time; duration; a systematic or/and orderly succession; a sequence, e.g. course of treatment; a mode of action or behavior; natural development, typical manner of proceeding.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE0FD98C-B485-595D-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-11","modifiedBy":"ONEDATA","dateModified":"2005-08-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE0FD98C-B486-595D-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-11","modifiedBy":"SBR","dateModified":"2008-12-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811835","version":"1","longName":"Melanoma","context":"CTEP"},{"publicId":"2811871","version":"1","longName":"Colorectal","context":"CTEP"},{"publicId":"2811831","version":"1","longName":"Breast","context":"CTEP"},{"publicId":"2811908","version":"1","longName":"Gynecologic","context":"CTEP"},{"publicId":"2811909","version":"1","longName":"Leukemia","context":"CTEP"},{"publicId":"2811950","version":"1","longName":"Multiple Myeloma","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"}]}],"AlternateNames":[{"name":"PR_TEM_AGT_ADM_CR_TP","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"Temozolomide treatment being","type":"Preferred Question Text","description":"Temozolomide treatment being reported","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Agent treatment being reported","url":null,"context":"CTEP"}],"origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"FE131197-6C65-304F-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-11","modifiedBy":"FORMBUILDER","dateModified":"2014-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}